Evidence map›Paper›PMID 34833952›Full record

ReviewMolecules (Basel, Switzerland)2021

Resveratrol against Cardiac Fibrosis: Research Progress in Experimental Animal Models.

Dongmin Yu, Zhixian Tang, Ben Li, Junjian Yu, Wentong Li, Ziyou Liu, Chengnan Tian

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Role of Gut Microbiota in Diabetic HFpEF: Mechanisms and Therapeutic Implications.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Bioactive Compounds and Cardiac Fibrosis: Current Insight and Future Prospect.Journal of cardiovascular development and disease · 2023
    Review
  12. Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Dongmin YuDepartment of Breast Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China.ORCID 0000-0002-8455-7425
Zhixian TangDepartment of Cardiothoracic Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China.
Ben LiDepartment of Cardiovascular Surgery, The First Affiliated Hospital with Nanjing Medical University, Nanjing 210029, China.
Junjian YuDepartment of Cardiothoracic Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China.
Wentong LiDepartment of Cardiothoracic Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China.
Ziyou LiuDepartment of Cardiothoracic Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China.
Chengnan TianDepartment of Cardiothoracic Surgery, First Affiliated Hospital of Gannan Medical University, Ganzhou 341000, China.
First Affiliated Hospital of Gannan Medical University · CNNanjing Medical University · CN

Funding

Jiangxi Provincial Department of Science and Technology key RESEARCH and development program 20192BBG70039National Natural Science Foundation of China 81960326
6 · The paper itself

Abstract

Cardiac fibrosis is a heterogeneous disease, which is characterized by abundant proliferation of interstitial collagen, disordered arrangement, collagen network reconstruction, increased cardiac stiffness, and decreased systolic and diastolic functions, consequently developing into cardiac insufficiency. With several factors participating in and regulating the occurrence and development of cardiac fibrosis, a complex molecular mechanism underlies the disease. Moreover, cardiac fibrosis is closely related to hypertension, myocardial infarction, viral myocarditis, atherosclerosis, and diabetes, which can lead to serious complications such as heart failure, arrhythmia, and sudden cardiac death, thus seriously threatening human life and health. Resveratrol, with the chemical name 3,5,4'-trihydroxy-trans-stilbene, is a polyphenol abundantly present in grapes and red wine. It is known to prevent the occurrence and development of cardiovascular diseases. In addition, it may resist cardiac fibrosis through a variety of growth factors, cytokines, and several cell signaling pathways, thus exerting a protective effect on the heart.

Indexed as

AnimalsAntifibrotic AgentsAntioxidantsDisease Models, AnimalHeartHeart DiseasesHumansMyocardiumResveratrolAntifibrotic AgentsAntioxidantsResveratrolcardiac fibrosiscardiac fibrosis-related diseasesresveratrol

Identifiers

PMID34833952
PMCPMC8621031
OpenAlexW3214015454

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.